{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:35:22Z","timestamp":1783578922409,"version":"3.55.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor microenvironment (TME) is complicated by the interaction of different cells of immune system, stromal components, and tumor-associated elements. Immune cells largely influence tumor progression by the means of various activating and inhibitory mechanisms including, immune checkpoint molecules. These molecules have been targeted for treating different types of cancers. For instance, blocking antibodies against CTLA-4, PD-1, or PD-L1 have elicited durable clinical responses and remarkable efficacy. These antibodies have also led to long-term remissions in a subset of patients, especially when used in combination therapies. V-domain immunoglobulin suppressor of T cell activation (VISTA) as a negative regulator of the immune system is expressed on multiple immune cell subsets including, myeloid-derived suppressor cells (MDSCs), macrophages, and lymphocytes. VISTA exerts regulatory effects and modulates T cell function and has shown prognostic significance in different cancers, leading to an increased attention regarding its suppressive role in the context of cancer. In this review, we will summarize the VISTA structure, ligands, role in the TME, and expression on immune cells. Furthermore, the significance of VISTA expression in the prognosis of cancer and its role in cancer immunotherapy, tumor resistance and ongoing clinical trials will be discussed.<\/jats:p>","DOI":"10.1007\/s12672-026-04407-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:26:03Z","timestamp":1770726363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["VISTA: bridging gaps in cancer immunotherapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Aida","family":"Khademolhosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Roshan","family":"Zamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moazzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mansourabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Safari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"4407_CR1","doi-asserted-by":"crossref","unstructured":"Satapathy S, Patro CS, Patro G, Panda M, Patra A. Cancer therapy. J Pharm Negat Results. 2023:3643\u20139.","DOI":"10.47750\/pnr.2023.14.02.429"},{"issue":"s2","key":"4407_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S, Papneja N, Miller W. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(s2):87\u201397.","journal-title":"Curr Oncol"},{"issue":"1","key":"4407_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Ca Cancer J Clin"},{"issue":"1","key":"4407_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication Signal. 2022;20(1):1\u201331.","journal-title":"Cell Communication Signal"},{"issue":"5","key":"4407_CR5","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"3","key":"4407_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/ph15030335","volume":"15","author":"P Pandey","year":"2022","unstructured":"Pandey P, Khan F, Qari HA, Upadhyay TK, Alkhateeb AF, Oves M. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals. 2022;15(3):335.","journal-title":"Pharmaceuticals"},{"key":"4407_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","volume":"65","author":"A Derer","year":"2016","unstructured":"Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. 2016;65:779\u201386.","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"4407_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"4407_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"19","key":"4407_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"5","key":"4407_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/eji.201646875","volume":"47","author":"L Dyck","year":"2017","unstructured":"Dyck L, Mills KH. Immune checkpoints and their Inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765\u201379.","journal-title":"Eur J Immunol"},{"key":"4407_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Experimental Clin Cancer Res. 2019;38:1\u201312.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"6","key":"4407_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Reviews Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"key":"4407_CR14","doi-asserted-by":"publisher","first-page":"625808","DOI":"10.3389\/fimmu.2021.625808","volume":"12","author":"X Xie","year":"2021","unstructured":"Xie X, Chen C, Chen W, Jiang J, Wang L, Li T, et al. Structural basis of VSIG3: the ligand for VISTA. Front Immunol. 2021;12:625808.","journal-title":"Front Immunol"},{"issue":"5","key":"4407_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci. 2019;116(5):1692\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"4407_CR16","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402X.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, et al. VISTA is highly expressed on MDSCs and mediates an Inhibition of T cell response in patients with AML. Oncoimmunology. 2018;7(9):e1469594.","journal-title":"Oncoimmunology"},{"key":"4407_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fimmu.2015.00418","volume":"6","author":"I Le Mercier","year":"2015","unstructured":"Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. 2015;6:418.","journal-title":"Front Immunol"},{"issue":"2","key":"4407_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/cei.13415","volume":"200","author":"M ElTanbouly","year":"2020","unstructured":"ElTanbouly M, Schaafsma E, Noelle R, Lines J, VISTA. Coming of age as a multi-lineage immune checkpoint. Clin Experimental Immunol. 2020;200(2):120\u201330.","journal-title":"Clin Experimental Immunol"},{"key":"4407_CR19","doi-asserted-by":"crossref","unstructured":"Tagliamento M, Agostinetto E, Borea R, Brand\u00e3o M, Poggio F, Addeo A et al. VISTA: a promising target for cancer immunotherapy? ImmunoTargets Therapy. 2021:185\u2013200.","DOI":"10.2147\/ITT.S260429"},{"issue":"6","key":"4407_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","volume":"2","author":"JL Lines","year":"2014","unstructured":"Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014;2(6):510\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"4407_CR21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1172\/JCI74589","volume":"124","author":"DB Flies","year":"2014","unstructured":"Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye JJ, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4\u2009+\u2009T cell\u2013mediated immunity. J Clin Investig. 2014;124(5):1966\u201375.","journal-title":"J Clin Investig"},{"issue":"7779","key":"4407_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370.","journal-title":"Nature"},{"key":"4407_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","volume":"10","author":"DO Khair","year":"2019","unstructured":"Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol. 2019;10:453.","journal-title":"Front Immunol"},{"issue":"18","key":"4407_CR24","doi-asserted-by":"publisher","first-page":"13742","DOI":"10.3390\/ijms241813742","volume":"24","author":"KE Duval","year":"2023","unstructured":"Duval KE, Tavakkoli AD, Kheirollah A, Soderholm HE, Demidenko E, Lines JL, et al. Enhancement of radiation therapy through Blockade of the immune Checkpoint, V-domain Ig suppressor of T cell activation (VISTA), in melanoma and adenocarcinoma murine models. Int J Mol Sci. 2023;24(18):13742.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4407_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","volume":"16","author":"J Mo","year":"2023","unstructured":"Mo J, Deng L, Peng K, Ouyang S, Ding W, Lou L, et al. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):15.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4407_CR26","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.ijrobp.2019.06.561","volume":"105","author":"J Kang","year":"2019","unstructured":"Kang J, Pilones K, Daviaud C, Kraynak J, Rodriguez-Ruiz M, Demaria S, et al. VISTA Blockade immunotherapy in a MULTI-modal approach to triple negative breast cancer (TNBC) in MICE and IMPACT on Microbiome. Int J Radiat Oncol Biol Phys. 2019;105(1):S88\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4407_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","volume":"33","author":"S Muller","year":"2020","unstructured":"Muller S, Lai WV, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2020;33(2):303\u201311.","journal-title":"Mod Pathol"},{"issue":"2","key":"4407_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41379-021-00901-y","volume":"35","author":"L Zong","year":"2022","unstructured":"Zong L, Mo S, Sun Z, Lu Z, Yu S, Chen J, et al. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer. Mod Pathol. 2022;35(2):266\u201373.","journal-title":"Mod Pathol"},{"issue":"5","key":"4407_CR29","doi-asserted-by":"publisher","first-page":"e1581546","DOI":"10.1080\/2162402X.2019.1581546","volume":"8","author":"H Loeser","year":"2019","unstructured":"Loeser H, Kraemer M, Gebauer F, Bruns C, Schr\u00f6der W, Zander T, et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1\/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology. 2019;8(5):e1581546.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4407_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-018-4435-1","volume":"18","author":"M Zhang","year":"2018","unstructured":"Zhang M, Pang H-J, Zhao W, Li Y-F, Yan L-X, Dong Z-Y, et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer. 2018;18(1):511.","journal-title":"BMC Cancer"},{"issue":"3","key":"4407_CR31","doi-asserted-by":"publisher","first-page":"e0278849","DOI":"10.1371\/journal.pone.0278849","volume":"18","author":"A Jlassi","year":"2023","unstructured":"Jlassi A, Manai M, Morjen M, Sahraoui G, Elasmi Allal M, ELBini-Dhouib I, et al. VISTA+\/CD8\u2009+\u2009status correlates with favorable prognosis in epithelial ovarian cancer. PLoS ONE. 2023;18(3):e0278849.","journal-title":"PLoS ONE"},{"key":"4407_CR32","doi-asserted-by":"crossref","unstructured":"Zheng M, Zhang Z, Yu L, Wang Z, Dong Y, Tong A et al. Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1194421"},{"key":"4407_CR33","doi-asserted-by":"crossref","unstructured":"ElTanbouly MA, Croteau W, Noelle RJ, Lines JL, editors. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Seminars in immunology. Elsevier; 2019.","DOI":"10.1016\/j.smim.2019.101308"},{"issue":"4","key":"4407_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","volume":"187","author":"DB Flies","year":"2011","unstructured":"Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(4):1537\u201341.","journal-title":"J Immunol"},{"issue":"3","key":"4407_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577\u201392.","journal-title":"J Exp Med"},{"issue":"7","key":"4407_CR36","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O\u2019Connell S, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74(7):1924\u201332.","journal-title":"Cancer Res"},{"issue":"10","key":"4407_CR37","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","volume":"28","author":"N Mehta","year":"2019","unstructured":"Mehta N, Maddineni S, Mathews II, Sperberg RAP, Huang P-S, Cochran JR. Structure and functional binding epitope of V-domain Ig suppressor of T cell activation. Cell Rep. 2019;28(10):2509\u201316. e5.","journal-title":"Cell Rep"},{"key":"4407_CR38","doi-asserted-by":"crossref","unstructured":"Slater BT, Han X, Chen L, Xiong Y. Structural insight into T cell coinhibition by PD-1H (VISTA). Proceedings of the National Academy of Sciences. 2020;117(3):1648-57.","DOI":"10.1073\/pnas.1908711117"},{"key":"4407_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fmed.2022.790995","volume":"9","author":"S Schlichtner","year":"2022","unstructured":"Schlichtner S, Yasinska IM, Ruggiero S, Berger SM, Aliu N, Prunk M, et al. Expression of the immune checkpoint protein Vista is differentially regulated by the TGF-\u03b21\u2013Smad3 signaling pathway in rapidly proliferating human cells and T lymphocytes. Front Med. 2022;9:196.","journal-title":"Front Med"},{"issue":"1","key":"4407_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","volume":"276","author":"EC Nowak","year":"2017","unstructured":"Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, et al. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276(1):66\u201379.","journal-title":"Immunol Rev"},{"issue":"5","key":"4407_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0006-291X(02)02025-9","volume":"296","author":"S Suzu","year":"2002","unstructured":"Suzu S, Hayashi Y, Harumi T, Nomaguchi K, Yamada M, Hayasawa H, et al. Molecular cloning of a novel Immunoglobulin superfamily gene preferentially expressed by brain and testis. Biochem Biophys Res Commun. 2002;296(5):1215\u201321.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4407_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-022-00394-0","volume":"10","author":"X-Y Tang","year":"2022","unstructured":"Tang X-Y, Xiong Y-L, Shi X-G, Zhao Y-B, Shi A-P, Zheng K-F, et al. IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. Biomark Res. 2022;10(1):49.","journal-title":"Biomark Res"},{"key":"4407_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mcn.2016.11.009","volume":"81","author":"C Matth\u00e4us","year":"2017","unstructured":"Matth\u00e4us C, Langhorst H, Sch\u00fctz L, J\u00fcttner R, Rathjen FG. Cell-cell communication mediated by the CAR subgroup of Immunoglobulin cell adhesion molecules in health and disease. Mol Cell Neurosci. 2017;81:32\u201340.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"4407_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nn.4176","volume":"19","author":"S Jang","year":"2016","unstructured":"Jang S, Oh D, Lee Y, Hosy E, Shin H, Van Riesen C, et al. Synaptic adhesion molecule IgSF11 regulates synaptic transmission and plasticity. Nat Neurosci. 2016;19(1):84\u201393.","journal-title":"Nat Neurosci"},{"issue":"52","key":"4407_CR45","doi-asserted-by":"publisher","first-page":"21490","DOI":"10.1074\/jbc.RA117.000113","volume":"292","author":"L Pelz","year":"2017","unstructured":"Pelz L, Purf\u00fcrst B, Rathjen FG. The cell adhesion molecule BT-IgSF is essential for a functional blood\u2013testis barrier and male fertility in mice. J Biol Chem. 2017;292(52):21490\u2013503.","journal-title":"J Biol Chem"},{"issue":"8","key":"4407_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1349-7006.2005.00073.x","volume":"96","author":"T Watanabe","year":"2005","unstructured":"Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, et al. Identification of Immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of Gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005;96(8):498\u2013506.","journal-title":"Cancer Sci"},{"issue":"1","key":"4407_CR47","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1038\/s41598-020-71519-4","volume":"10","author":"N Mehta","year":"2020","unstructured":"Mehta N, Maddineni S, Kelly RL, Lee RB, Hunter SA, Silberstein JL, et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020;10(1):15171.","journal-title":"Sci Rep"},{"issue":"1","key":"4407_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","volume":"156","author":"J Wang","year":"2019","unstructured":"Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C, et al. VSIG-3 as a ligand of VISTA inhibits human T\u2010cell function. Immunology. 2019;156(1):74\u201385.","journal-title":"Immunology"},{"key":"4407_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","volume":"22","author":"IG Silva","year":"2017","unstructured":"Silva IG, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, et al. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44\u201357.","journal-title":"EBioMedicine"},{"key":"4407_CR50","doi-asserted-by":"publisher","first-page":"580557","DOI":"10.3389\/fimmu.2020.580557","volume":"11","author":"IM Yasinska","year":"2020","unstructured":"Yasinska IM, Meyer NH, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M, et al. Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity. Front Immunol. 2020;11:580557.","journal-title":"Front Immunol"},{"key":"4407_CR51","doi-asserted-by":"crossref","unstructured":"Schlichtner S, Yasinska IM, Lall GS, Berger SM, Ruggiero S, Cholewa D et al. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins. Journal for immunotherapy of cancer. 2023;11(1).","DOI":"10.1136\/jitc-2022-005714"},{"issue":"5","key":"4407_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.it.2017.02.002","volume":"38","author":"R Tinoco","year":"2017","unstructured":"Tinoco R, Otero DC, Takahashi AA, Bradley LM. PSGL-1: a new player in the immune checkpoint landscape. Trends Immunol. 2017;38(5):323\u201335.","journal-title":"Trends Immunol"},{"issue":"1","key":"4407_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2148-7-166","volume":"7","author":"B Ba\u00efsse","year":"2007","unstructured":"Ba\u00efsse B, Galisson F, Giraud S, Schapira M, Spertini O. Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function. BMC Evol Biol. 2007;7(1):1\u201315.","journal-title":"BMC Evol Biol"},{"issue":"5","key":"4407_CR54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1189\/jlb.0209117","volume":"86","author":"A Zarbock","year":"2009","unstructured":"Zarbock A, M\u00fcller H, Kuwano Y, Ley K. PSGL-1\u2010dependent myeloid leukocyte activation. J Leukoc Biol. 2009;86(5):1119\u201324.","journal-title":"J Leukoc Biol"},{"issue":"9","key":"4407_CR55","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"4407_CR56","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.immuni.2016.04.015","volume":"44","author":"R Tinoco","year":"2016","unstructured":"Tinoco R, Carrette F, Barraza ML, Otero DC, Maga\u00f1a J, Bosenberg MW, et al. PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion. Immunity. 2016;44(5):1190\u2013203.","journal-title":"Immunity"},{"issue":"1","key":"4407_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41590-019-0563-2","volume":"21","author":"KM Mahoney","year":"2020","unstructured":"Mahoney KM, Freeman GJ. Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2020;21(1):13\u20136.","journal-title":"Nat Immunol"},{"key":"4407_CR58","doi-asserted-by":"crossref","unstructured":"Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A et al. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in Treatment-na\u00efve melanoma patients: implications for clinical trials. 2019;25(11):3247\u201358.","DOI":"10.1158\/1078-0432.CCR-18-4011"},{"issue":"1","key":"4407_CR59","doi-asserted-by":"publisher","first-page":"21504","DOI":"10.1038\/s41598-021-00835-0","volume":"11","author":"A Ghouzlani","year":"2021","unstructured":"Ghouzlani A, Lakhdar A, Rafii S, Karkouri M, Badou A. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis. Sci Rep. 2021;11(1):21504.","journal-title":"Sci Rep"},{"key":"4407_CR60","doi-asserted-by":"publisher","first-page":"563044","DOI":"10.3389\/fimmu.2020.563044","volume":"11","author":"X Xie","year":"2020","unstructured":"Xie X, Zhang J, Shi Z, Liu W, Hu X, Qie C, et al. The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer. Front Immunol. 2020;11:563044.","journal-title":"Front Immunol"},{"key":"4407_CR61","doi-asserted-by":"publisher","first-page":"1154631","DOI":"10.3389\/fonc.2023.1154631","volume":"13","author":"I Rezouki","year":"2023","unstructured":"Rezouki I, Zohair B, Ssi SA, Karkouri M, Razzouki I, Elkarroumi M, et al. High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. Front Oncol. 2023;13:1154631.","journal-title":"Front Oncol"},{"issue":"1","key":"4407_CR62","doi-asserted-by":"publisher","first-page":"1907059","DOI":"10.1080\/2162402X.2021.1907059","volume":"10","author":"HX He","year":"2021","unstructured":"He HX, Gao Y, Fu JC, Zhou QH, Wang XX, Bai B, et al. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma. Oncoimmunology. 2021;10(1):1907059.","journal-title":"Oncoimmunology"},{"key":"4407_CR63","doi-asserted-by":"crossref","unstructured":"Hong S, Yuan Q, Xia H, Zhu G, Feng Y, Wang Q et al. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. 2019;10(11):840\u20135.","DOI":"10.1007\/s13238-019-0642-z"},{"key":"4407_CR64","doi-asserted-by":"crossref","unstructured":"Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. 2018;67(11):1685\u201394.","DOI":"10.1007\/s00262-018-2227-8"},{"key":"4407_CR65","doi-asserted-by":"publisher","first-page":"583966","DOI":"10.3389\/fonc.2020.583966","volume":"10","author":"X Cao","year":"2020","unstructured":"Cao X, Ren X, Zhou Y, Mao F, Lin Y, Wu H, et al. VISTA expression on immune cells correlates with favorable prognosis in patients with Triple-Negative breast cancer. Front Oncol. 2020;10:583966.","journal-title":"Front Oncol"},{"issue":"8","key":"4407_CR66","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.3390\/cancers15082326","volume":"15","author":"D Digomann","year":"2023","unstructured":"Digomann D, Strack J, Heiduk M, Plesca I, Rupp L, Reiche C, et al. VISTA ligation reduces antitumor T-Cell activity in pancreatic cancer. Cancers. 2023;15(8):2326.","journal-title":"Cancers"},{"issue":"2","key":"4407_CR67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.celrep.2019.12.036","volume":"30","author":"SR Rosenbaum","year":"2020","unstructured":"Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, et al. FOXD3 regulates VISTA expression in melanoma. Cell Rep. 2020;30(2):510\u2013. \u2013\u200924.e6.","journal-title":"Cell Rep"},{"issue":"1","key":"4407_CR68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1600-6143.2003.00293.x","volume":"4","author":"S Fu","year":"2004","unstructured":"Fu S, Yopp AC, Mao X, Chen D, Zhang N, Chen D, et al. CD4\u2009+\u2009CD25\u2009+\u2009CD62\u2009+\u2009T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant. 2004;4(1):65\u201378.","journal-title":"Am J Transplant"},{"key":"4407_CR69","doi-asserted-by":"crossref","unstructured":"Zong L, Mo S, Yu S. Expression of the immune checkpoint VISTA in breast cancer. 2020;69(8):1437\u201346.","DOI":"10.1007\/s00262-020-02554-3"},{"issue":"4","key":"4407_CR70","doi-asserted-by":"publisher","first-page":"e1293215","DOI":"10.1080\/2162402X.2017.1293215","volume":"6","author":"C B\u00f6ger","year":"2017","unstructured":"B\u00f6ger C, Behrens HM, Kr\u00fcger S, R\u00f6cken C. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1\/PD-1: A future perspective for a combined gastric cancer therapy? Oncoimmunology. 2017;6(4):e1293215.","journal-title":"Oncoimmunology"},{"key":"4407_CR71","doi-asserted-by":"crossref","unstructured":"Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. 2020;69(1):33\u201342.","DOI":"10.1007\/s00262-019-02434-5"},{"key":"4407_CR72","doi-asserted-by":"crossref","unstructured":"Zong L, Gu Y. Expression of B7 family checkpoint proteins in cervical cancer. 2022;35(6):786\u201393.","DOI":"10.1038\/s41379-021-00979-4"},{"key":"4407_CR73","doi-asserted-by":"crossref","unstructured":"Seo WI, Lee CH, Jung SJ. Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer. 2021;70(11):3113\u201322.","DOI":"10.1007\/s00262-021-02906-7"},{"key":"4407_CR74","doi-asserted-by":"crossref","unstructured":"Zong L, Mo S, Sun Z, Lu Z, Yu S. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer. 2022;35(2):266\u201373.","DOI":"10.1038\/s41379-021-00901-y"},{"key":"4407_CR75","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00432-020-03463-9","volume":"147","author":"Z Hou","year":"2021","unstructured":"Hou Z, Pan Y, Fei Q, Lin Y, Zhou Y, Liu Y, et al. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. J Cancer Res Clin Oncol. 2021;147:517\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4407_CR76","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","volume":"67","author":"LF Kuklinski","year":"2018","unstructured":"Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67:1113\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"4407_CR77","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","volume":"24","author":"F Villarroel-Espindola","year":"2018","unstructured":"Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, et al. Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non\u2013small cell lung cancer. Clin Cancer Res. 2018;24(7):1562\u201373.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4407_CR78","first-page":"22","volume":"44","author":"L Zong","year":"2021","unstructured":"Zong L, Yu S, Mo S, Zhou Y, Xiang Y, Lu Z, et al., et al. High VISTA expression correlates with a favorable prognosis in patients with colorectal cancer. J Immunotherapy (Hagerstown Md: 1997). 2021;44(1):22\u20138.","journal-title":"J Immunotherapy (Hagerstown Md: 1997)"},{"issue":"1","key":"4407_CR79","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1038\/s41598-020-71216-2","volume":"10","author":"JW Choi","year":"2020","unstructured":"Choi JW, Kim YJ, Yun KA, Won CH, Lee MW, Choi JH, et al. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression. Sci Rep. 2020;10(1):14372.","journal-title":"Sci Rep"},{"key":"4407_CR80","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3389\/fimmu.2022.837097","volume":"13","author":"GA Noubissi Nzeteu","year":"2022","unstructured":"Noubissi Nzeteu GA, Schlichtner S, David S, Ruppenstein A, Fasler-Kan E, Raap U, et al. Macrophage differentiation and polarization regulate the release of the immune checkpoint protein V-domain Ig suppressor of T cell activation. Front Immunol. 2022;13:2135.","journal-title":"Front Immunol"},{"key":"4407_CR81","doi-asserted-by":"publisher","first-page":"585214","DOI":"10.3389\/fimmu.2020.585214","volume":"11","author":"X Gao","year":"2021","unstructured":"Gao X, Sui H, Zhao S, Gao X, Su Y, Qu P. Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumor microenvironment. Front Immunol. 2021;11:585214.","journal-title":"Front Immunol"},{"issue":"7","key":"4407_CR82","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.CIR-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng J, Li J, Sarde A, Lines JL, Lee Y-C, Qian DC, et al. Hypoxia-Induced VISTA promotes the suppressive function of Myeloid-Derived suppressor cells in the tumor MicroenvironmentHypoxia-Induced VISTA promotes immunosuppression. Cancer Immunol Res. 2019;7(7):1079\u201390.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"4407_CR83","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7):1933\u201344.","journal-title":"Cancer Res"},{"issue":"6475","key":"4407_CR84","doi-asserted-by":"publisher","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","volume":"367","author":"MA ElTanbouly","year":"2020","unstructured":"ElTanbouly MA, Zhao Y, Nowak E, Li J, Schaafsma E, Le Mercier I, et al. VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance. Science. 2020;367(6475):eaay0524.","journal-title":"Science"},{"key":"4407_CR85","first-page":"1","volume":"18","author":"M Zhang","year":"2018","unstructured":"Zhang M, Pang H-J, Zhao W, Li Y-F, Yan L-X, Dong Z-Y, et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer. 2018;18:1\u20138.","journal-title":"BMC Cancer"},{"issue":"5","key":"4407_CR86","first-page":"707","volume":"22","author":"S Ma","year":"2022","unstructured":"Ma S, Qin L, Wang X, Wang W, Li J, Wang H, et al. The expression of VISTA on CD4\u2009+\u2009T cells associate with poor prognosis and immune status in non-small cell lung cancer patients. Bosnian J Basic Med Sci. 2022;22(5):707\u201315.","journal-title":"Bosnian J Basic Med Sci"},{"key":"4407_CR87","doi-asserted-by":"publisher","first-page":"961374","DOI":"10.3389\/fonc.2022.961374","volume":"12","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhang J, Liu N, Wang B, Zhou Y, Yang J. VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC. Front Oncol. 2022;12:961374.","journal-title":"Front Oncol"},{"issue":"1","key":"4407_CR88","doi-asserted-by":"publisher","first-page":"1708065","DOI":"10.1080\/2162402X.2019.1708065","volume":"9","author":"S Kato","year":"2020","unstructured":"Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, et al. Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020;9(1):1708065.","journal-title":"Oncoimmunology"},{"issue":"12","key":"4407_CR89","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666\u201376.","journal-title":"Mod Pathol"},{"issue":"5","key":"4407_CR90","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551\u20135.","journal-title":"Nat Med"},{"issue":"2","key":"4407_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tranon.2019.11.004","volume":"13","author":"H Schoop","year":"2020","unstructured":"Schoop H, Bregenzer A, Halske C, Behrens HM, Kr\u00fcger S, Egberts JH, et al. Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint Inhibitors-Comparison against a therapy Na\u00efve cohort. Translational Oncol. 2020;13(2):165\u201376.","journal-title":"Translational Oncol"},{"issue":"7","key":"4407_CR92","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1007\/s00432-022-04329-y","volume":"149","author":"\u0141 Zapa\u0142a","year":"2023","unstructured":"Zapa\u0142a \u0141, Kunc M, Sharma S, P\u0119ksa R, Pop\u0119da M, Biernat W, et al. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus. J Cancer Res Clin Oncol. 2023;149(7):4131\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4407_CR93","doi-asserted-by":"crossref","unstructured":"Saleh R, Taha RZ, Toor SM, Sasidharan Nair V, Murshed K, Khawar M et al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. 2020;69(10):1989\u201399.","DOI":"10.1007\/s00262-020-02593-w"},{"issue":"1","key":"4407_CR94","doi-asserted-by":"publisher","first-page":"17426","DOI":"10.1038\/s41598-021-96417-1","volume":"11","author":"D Wu","year":"2021","unstructured":"Wu D, Hacking S, Vitkovski T, Nasim M. Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment. Sci Rep. 2021;11(1):17426.","journal-title":"Sci Rep"},{"issue":"3","key":"4407_CR95","first-page":"3465","volume":"16","author":"H Liao","year":"2018","unstructured":"Liao H, Zhu H, Liu S, Wang H. Expression of V-domain Immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett. 2018;16(3):3465\u201372.","journal-title":"Oncol Lett"},{"issue":"4","key":"4407_CR96","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jiph.2023.01.019","volume":"16","author":"W Zou","year":"2023","unstructured":"Zou W, Huang R, Li P, Liu X, Huang Q, Yue J, et al. Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer. J Infect Public Health. 2023;16(4):542\u201350.","journal-title":"J Infect Public Health"},{"issue":"3","key":"4407_CR97","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/ijms24032160","volume":"24","author":"FN Loch","year":"2023","unstructured":"Loch FN, Kamphues C, Beyer K, Schineis C, Rayya W, Lauscher JC, et al. The immune checkpoint landscape in tumor cells of pancreatic ductal adenocarcinoma. Int J Mol Sci. 2023;24(3):2160.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4407_CR98","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5858\/arpa.2021-0377-OA","volume":"147","author":"S Mo","year":"2023","unstructured":"Mo S, Zong L, Chen X, Ban X, Li M, Lu Z, et al. Expression and prognostic value of B7 family immune checkpoints in pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2023;147(2):193\u2013201.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"4407_CR99","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","volume":"66","author":"L Wu","year":"2017","unstructured":"Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao L, et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunotherapy: CII. 2017;66(5):627\u201336.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"4407_CR100","doi-asserted-by":"crossref","unstructured":"Starzy\u0144ska A, Sobocki BK. VISTA H-Score is significantly associated with a 5-Year DFS rate in. Oral Squamous Cell Carcinoma. 2023;12(4).","DOI":"10.3390\/jcm12041619"},{"key":"4407_CR101","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fonc.2018.00269","volume":"8","author":"R Shrestha","year":"2018","unstructured":"Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front Oncol. 2018;8:269.","journal-title":"Front Oncol"},{"key":"4407_CR102","doi-asserted-by":"crossref","unstructured":"Albertsmeier M, Altendorf-Hofmann A, Lindner LH. VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy? 2022;14(4).","DOI":"10.3390\/cancers14041006"},{"issue":"1","key":"4407_CR103","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41598-020-59608-w","volume":"10","author":"XL He","year":"2020","unstructured":"He XL, Zhou Y, Lu HZ, Li QX, Wang Z. Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2662.","journal-title":"Sci Rep"},{"key":"4407_CR104","doi-asserted-by":"crossref","unstructured":"Long L, Zhang L. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma. 2022;14(6):419\u201331.","DOI":"10.2217\/imt-2021-0093"},{"issue":"7","key":"4407_CR105","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00262-020-02530-x","volume":"69","author":"D Tronik-Le Roux","year":"2020","unstructured":"Tronik-Le Roux D, Sautreuil M, Bentriou M, V\u00e9rine J, Palma MB, Daouya M, et al. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets. Cancer Immunol Immunotherapy: CII. 2020;69(7):1237\u201352.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"issue":"1","key":"4407_CR106","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/ijo.2020.5062","volume":"57","author":"M Kitsou","year":"2020","unstructured":"Kitsou M, Ayiomamitis GD, Zaravinos A. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. Int J Oncol. 2020;57(1):237\u201348.","journal-title":"Int J Oncol"},{"issue":"2","key":"4407_CR107","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/biology12020218","volume":"12","author":"S Dutta","year":"2023","unstructured":"Dutta S, Ganguly A, Chatterjee K, Spada S, Mukherjee S. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology. 2023;12(2):218.","journal-title":"Biology"},{"key":"4407_CR108","doi-asserted-by":"crossref","unstructured":"Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S et al. Rationally targeted anti-VISTA antibody that Blockades the C-C\u2019loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. J Immunother Cancer. 2022;10(2).","DOI":"10.1136\/jitc-2021-003382"},{"issue":"1","key":"4407_CR109","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","volume":"120","author":"K Mulati","year":"2019","unstructured":"Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115\u201327.","journal-title":"Br J Cancer"},{"key":"4407_CR110","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","volume":"57","author":"Y Kondo","year":"2016","unstructured":"Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016;57:54\u201360.","journal-title":"Oral Oncol"},{"issue":"11","key":"4407_CR111","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/cancers11111756","volume":"11","author":"K Marhelava","year":"2019","unstructured":"Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers. 2019;11(11):1756.","journal-title":"Cancers"},{"issue":"1","key":"4407_CR112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biology. 2021;4(1):699.","journal-title":"Commun Biology"},{"issue":"23","key":"4407_CR113","first-page":"7412","volume":"15","author":"VS Radhakrishnan","year":"2009","unstructured":"Radhakrishnan VS, Bakhshi S, Prabhash K, Deshmukh C, Nag S, Lakshmaiah K, et al. Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients with advanced solid tumor and hodgkin lymphoma. Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Cancer Res"},{"key":"4407_CR114","doi-asserted-by":"crossref","unstructured":"Rodon Ahnert J, Gruber JJ, Telli ML, Mita MM, Mita AC, Kim JW, et al. A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2664"},{"key":"4407_CR115","doi-asserted-by":"crossref","unstructured":"Martinez E, Faris J, Von Roemeling R, Angelides S, Johnson M. 392 phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies. BMJ Specialist Journals; 2020.","DOI":"10.1136\/jitc-2020-SITC2020.0392"},{"issue":"Suppl 2","key":"4407_CR116","first-page":"A349","volume":"9","author":"F Scott","year":"2021","unstructured":"Scott F, Wichmann C, Burvenich I, McDonald A, Guo N, Rigopoulos A, et al. 324 preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model. J Immunother Cancer. 2021;9(Suppl 2):A349\u2013A.","journal-title":"J Immunother Cancer"},{"key":"4407_CR117","doi-asserted-by":"crossref","unstructured":"Marabelle A, Jungels C, De Bono J, Vey N, Wermke M, Garralda E, et al. 316 EVICTION study: preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. BMJ Specialist Journals; 2020.","DOI":"10.1136\/jitc-2020-SITC2020.0316"},{"key":"4407_CR118","doi-asserted-by":"crossref","unstructured":"Guillaudeux T, Iadonato S, Tarcha E, Philips C. 268 KVA 12.1 a novel fully human anti-VISTA antibody: clinical trial design in monotherapy and in combination with an anti-PD1 antibody. BMJ Specialist Journals; 2021.","DOI":"10.1136\/jitc-2021-SITC2021.268"},{"issue":"2","key":"4407_CR119","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/nsr\/nwx062","volume":"5","author":"L Feng","year":"2018","unstructured":"Feng L, Dong Z, Tao D, Zhang Y, Liu Z. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5(2):269\u201386.","journal-title":"Natl Sci Rev"},{"key":"4407_CR120","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fphys.2013.00354","volume":"4","author":"CR Justus","year":"2013","unstructured":"Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol. 2013;4:354.","journal-title":"Front Physiol"},{"issue":"1","key":"4407_CR121","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1038\/s41598-020-70396-1","volume":"10","author":"N Piasentin","year":"2020","unstructured":"Piasentin N, Milotti E, Chignola R. The control of acidity in tumor cells: A biophysical model. Sci Rep. 2020;10(1):13613.","journal-title":"Sci Rep"},{"key":"4407_CR122","doi-asserted-by":"publisher","first-page":"979154","DOI":"10.3389\/fonc.2022.979154","volume":"12","author":"A Bogdanov","year":"2022","unstructured":"Bogdanov A, Bogdanov A, Chubenko V, Volkov N, Moiseenko F, Moiseyenko V. Tumor acidity: from hallmark of cancer to target of treatment. Front Oncol. 2022;12:979154.","journal-title":"Front Oncol"},{"issue":"2","key":"4407_CR123","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00432-020-03463-9","volume":"147","author":"Z Hou","year":"2021","unstructured":"Hou Z, Pan Y, Fei Q, Lin Y, Zhou Y, Liu Y, et al. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. J Cancer Res Clin Oncol. 2021;147(2):517\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4407_CR124","doi-asserted-by":"crossref","unstructured":"Starzy\u0144ska A, Sobocki BK, Sakowicz-Burkiewicz M, Jereczek-Fossa BA, Alterio D, Szot O et al. VISTA H-Score is significantly associated with a 5-Year DFS rate in oral squamous cell carcinoma. J Clin Med. 2023;12(4).","DOI":"10.3390\/jcm12041619"},{"key":"4407_CR125","doi-asserted-by":"crossref","unstructured":"Loch FN, Kamphues C, Beyer K, Schineis C, Rayya W, Lauscher JC et al. The immune checkpoint landscape in tumor cells of pancreatic ductal adenocarcinoma. Int J Mol Sci. 2023;24(3).","DOI":"10.3390\/ijms24032160"},{"issue":"21","key":"4407_CR126","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015;112(21):6682\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"4407_CR127","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","volume":"67","author":"LF Kuklinski","year":"2018","unstructured":"Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67(7):1113\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4407_CR128","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00262-019-02434-5","volume":"69","author":"L Zong","year":"2020","unstructured":"Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother. 2020;69(1):33\u201342.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"4407_CR129","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00262-020-02593-w","volume":"69","author":"R Saleh","year":"2020","unstructured":"Saleh R, Taha RZ, Toor SM, Sasidharan Nair V, Murshed K, Khawar M, et al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol Immunother. 2020;69(10):1989\u201399.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"4407_CR130","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13238-019-0642-z","volume":"10","author":"S Hong","year":"2019","unstructured":"Hong S, Yuan Q, Xia H, Zhu G, Feng Y, Wang Q, et al. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein Cell. 2019;10(11):840\u20135.","journal-title":"Protein Cell"},{"issue":"12","key":"4407_CR131","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RP, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666\u201376.","journal-title":"Mod Pathol"},{"issue":"1","key":"4407_CR132","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","volume":"11","author":"E Schaafsma","year":"2023","unstructured":"Schaafsma E, Croteau W, ElTanbouly M, Nowak EC, Smits NC, Deng J, et al. VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance. Cancer Immunol Res. 2023;11(1):38\u201355.","journal-title":"Cancer Immunol Res"},{"key":"4407_CR133","doi-asserted-by":"crossref","unstructured":"Zhang Y, Hu J, Ji K, Jiang S, Dong Y, Sun L et al. CD39 Inhibition and VISTA Blockade May overcome radiotherapy resistance by targeting exhausted CD8\u2009+\u2009T cells and immunosuppressive myeloid cells. Cell Rep Med. 2023;4(8).","DOI":"10.1016\/j.xcrm.2023.101151"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04407-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:03:00Z","timestamp":1779688980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04407-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4407"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04407-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"783"}}